Sophia Genetics Sa (SOPH)

$4.73

-0.01

(-0.21%)

Market is closed - opens 7 PM, 28 May 2024

Insights on Sophia Genetics Sa

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 17.04M → 15.77M (in $), with an average decrease of 7.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -24.06M → -13.70M (in $), with an average increase of 75.6% per quarter

  • Vs HQY

    In the last 1 year, Healthequity Inc has given 41.3% return, outperforming this stock by 33.1%

Performance

  • $4.71
    $4.82
    $4.73
    downward going graph

    0.42%

    Downside

    Day's Volatility :2.28%

    Upside

    1.87%

    downward going graph
  • $2.13
    $7.37
    $4.73
    downward going graph

    54.97%

    Downside

    52 Weeks Volatility :71.1%

    Upside

    35.82%

    downward going graph

Returns

PeriodSophia Genetics SaSector (Health Care)Index (Russel 2000)
3 Months
-1.25%
-2.3%
0.0%
6 Months
24.15%
10.1%
0.0%
1 Year
8.24%
13.0%
0.0%
3 Years
-71.78%
16.4%
-19.8%

Highlights

Market Capitalization
309.9M
Book Value
$2.32
Earnings Per Share (EPS)
-1.22
Wall Street Target Price
8.67
Profit Margin
-126.63%
Operating Margin TTM
-110.98%
Return On Assets TTM
-20.78%
Return On Equity TTM
-44.93%
Revenue TTM
62.4M
Revenue Per Share TTM
0.96
Quarterly Revenue Growth YOY
27.400000000000002%
Gross Profit TTM
31.3M
EBITDA
-72.9M
Diluted Eps TTM
-1.22
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.93
EPS Estimate Next Year
-0.81
EPS Estimate Current Quarter
-0.27
EPS Estimate Next Quarter
-0.25

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Sophia Genetics Sa(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
9
9
Hold
1
1
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 83.3%

Current $4.73
Target $8.67

Company Financials

FY19Y/Y Change
Revenue
25.4M
-
Net Income
-33.8M
-
Net Profit Margin
-133.23%
-
FY20Y/Y Change
Revenue
28.4M
↑ 11.98%
Net Income
-39.3M
↑ 16.42%
Net Profit Margin
-138.52%
↓ 5.29%
FY21Y/Y Change
Revenue
40.5M
↑ 42.43%
Net Income
-73.7M
↑ 87.28%
Net Profit Margin
-182.14%
↓ 43.62%
FY22Y/Y Change
Revenue
47.6M
↑ 17.58%
Net Income
-87.4M
↑ 18.7%
Net Profit Margin
-183.87%
↓ 1.73%
FY23Y/Y Change
Revenue
62.4M
↑ 31.14%
Net Income
-79.0M
↓ 9.68%
Net Profit Margin
-126.63%
↑ 57.24%
Q4 FY22Q/Q Change
Revenue
13.4M
↑ 14.9%
Net Income
-14.0M
↓ 40.06%
Net Profit Margin
-104.39%
↑ 95.73%
Q1 FY23Q/Q Change
Revenue
14.0M
↑ 4.35%
Net Income
-19.7M
↑ 41.01%
Net Profit Margin
-141.06%
↓ 36.67%
Q2 FY23Q/Q Change
Revenue
15.1M
↑ 7.79%
Net Income
-21.4M
↑ 8.61%
Net Profit Margin
-142.13%
↓ 1.07%
Q3 FY23Q/Q Change
Revenue
16.3M
↑ 8.3%
Net Income
-13.8M
↓ 35.39%
Net Profit Margin
-84.79%
↑ 57.34%
Q4 FY23Q/Q Change
Revenue
17.0M
↑ 4.57%
Net Income
-24.1M
↑ 74.05%
Net Profit Margin
-141.14%
↓ 56.35%
Q1 FY24Q/Q Change
Revenue
15.8M
↓ 7.44%
Net Income
-13.7M
↓ 43.04%
Net Profit Margin
-86.85%
↑ 54.29%
FY18Y/Y Change
Total Assets
76.6M
-
Total Liabilities
21.8M
-
FY19Y/Y Change
Total Assets
51.7M
↓ 32.58%
Total Liabilities
29.4M
↑ 34.85%
FY20Y/Y Change
Total Assets
132.1M
↑ 155.76%
Total Liabilities
31.6M
↑ 7.49%
FY21Y/Y Change
Total Assets
320.2M
↑ 142.34%
Total Liabilities
44.8M
↑ 41.66%
FY22Y/Y Change
Total Assets
243.8M
↓ 23.84%
Total Liabilities
43.7M
↓ 2.38%
FY23Y/Y Change
Total Assets
206.2M
↓ 15.45%
Total Liabilities
54.7M
↑ 25.18%
Q4 FY22Q/Q Change
Total Assets
243.8M
↓ 2.69%
Total Liabilities
43.7M
↓ 2.21%
Q1 FY23Q/Q Change
Total Assets
232.1M
↓ 4.83%
Total Liabilities
47.1M
↑ 7.87%
Q2 FY23Q/Q Change
Total Assets
223.2M
↓ 3.82%
Total Liabilities
51.5M
↑ 9.24%
Q3 FY23Q/Q Change
Total Assets
205.9M
↓ 7.77%
Total Liabilities
47.4M
↓ 7.94%
Q4 FY23Q/Q Change
Total Assets
206.2M
↑ 0.15%
Total Liabilities
54.7M
↑ 15.4%
Q1 FY24Q/Q Change
Total Assets
180.3M
↓ 12.56%
Total Liabilities
48.0M
↓ 12.22%
FY19Y/Y Change
Operating Cash Flow
-31.7M
-
Investing Cash Flow
-3.0M
-
Financing Cash Flow
-1.0M
-
FY20Y/Y Change
Operating Cash Flow
-31.7M
↑ 0.16%
Investing Cash Flow
-24.3M
↑ 701.95%
Financing Cash Flow
107.0M
↓ 10563.83%
FY21Y/Y Change
Operating Cash Flow
-57.9M
↑ 82.6%
Investing Cash Flow
-56.9M
↑ 134.07%
Financing Cash Flow
237.8M
↑ 122.12%
FY22Y/Y Change
Operating Cash Flow
-70.1M
↑ 20.98%
Investing Cash Flow
42.0M
↓ 173.72%
Financing Cash Flow
-1.6M
↓ 100.66%
Q4 FY22Q/Q Change
Operating Cash Flow
-10.3M
↓ 54.74%
Investing Cash Flow
12.1M
↑ 287.55%
Financing Cash Flow
-580.0K
↓ 28.31%
Q1 FY23Q/Q Change
Operating Cash Flow
-14.8M
↑ 43.18%
Investing Cash Flow
-1.8M
↓ 114.96%
Financing Cash Flow
-935.0K
↑ 61.21%
Q2 FY23Q/Q Change
Operating Cash Flow
-10.3M
↓ 30.19%
Investing Cash Flow
-1.8M
↑ 0.0%
Financing Cash Flow
-619.0K
↓ 33.8%
Q3 FY23Q/Q Change
Operating Cash Flow
-12.2M
↑ 17.88%
Investing Cash Flow
-2.1M
↑ 15.69%
Financing Cash Flow
-757.0K
↑ 22.29%

Technicals Summary

Sell

Neutral

Buy

Sophia Genetics Sa is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sophia Genetics Sa
Sophia Genetics Sa
-4.44%
24.15%
8.24%
-71.78%
-71.78%
Solventum Corp
Solventum Corp
-2.23%
-12.52%
-12.52%
-12.52%
-12.52%
Veeva Systems Inc.
Veeva Systems Inc.
2.41%
17.63%
25.19%
-22.96%
46.12%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-7.1%
12.24%
-0.01%
32.01%
32.01%
Healthequity Inc
Healthequity Inc
0.29%
18.1%
41.25%
0.33%
15.81%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sophia Genetics Sa
Sophia Genetics Sa
NA
NA
NA
-0.93
-0.45
-0.21
NA
2.32
Solventum Corp
Solventum Corp
NA
NA
NA
6.26
0.17
0.08
NA
NA
Veeva Systems Inc.
Veeva Systems Inc.
63.73
63.73
1.35
4.76
0.13
0.05
NA
28.8
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
23.25
23.25
20.11
4.27
0.22
0.06
0.0
16.23
Healthequity Inc
Healthequity Inc
124.16
124.16
2.29
2.19
0.03
0.03
NA
23.63
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sophia Genetics Sa
Sophia Genetics Sa
Buy
$309.9M
-71.78%
NA
-126.63%
Solventum Corp
Solventum Corp
NA
$10.8B
-12.52%
NA
15.73%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$33.1B
46.12%
63.73
22.24%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$36.5B
32.01%
23.25
8.05%
Healthequity Inc
Healthequity Inc
Buy
$6.9B
15.81%
124.16
5.57%

Institutional Holdings

  • Banque Pictet & Cie SA

    3.36%
  • Alta Wealth Advisors LLC

    2.16%
  • Principal Financial Group Inc

    1.54%
  • Essex Investment Management Company, LLC

    0.40%
  • Legato Capital Management LLC

    0.16%
  • Compagnie Lombard, Odier SCA

    0.02%

Company Information

sophia genetics, world's largest clinical genomics community, brings together expertise in genetics, bioinformatics, machine learning and genomic privacy. based in switzerland, we are known for our high medical standards and swiss precision. sophia genetics offers health professionals who perform clinical genetic testing unparalleled bioinformatics analysis, quality assurance and secure banking of patient dna sequence data generated by ngs. the company helps clinical laboratories to reduce costs, overcome complexity, significantly improve the turnaround time for routine diagnosis and meet quality requirements related to the use of ngs in the clinic. our solution, the sophia ddm™ platform allows hospitals to better and faster diagnose patients using cutting edge ngs analytics algorithms and through knowledge sharing within the largest clinical genomics community in the world (+100 hospitals). the name « sophia » means wisdom in greek and it is the definition of our excellence based

Organization
Sophia Genetics Sa
Employees
430
CEO
Dr. Jurgi Camblong M.B.A., Ph.D.
Industry
Technology

FAQs